HK1005166A1 - Gabapentin and its derivatives for treating neurodegenerative diseases - Google Patents

Gabapentin and its derivatives for treating neurodegenerative diseases

Info

Publication number
HK1005166A1
HK1005166A1 HK98104232A HK98104232A HK1005166A1 HK 1005166 A1 HK1005166 A1 HK 1005166A1 HK 98104232 A HK98104232 A HK 98104232A HK 98104232 A HK98104232 A HK 98104232A HK 1005166 A1 HK1005166 A1 HK 1005166A1
Authority
HK
Hong Kong
Prior art keywords
gabapentin
treating neurodegenerative
derivatives
neurodegenerative diseases
huntington
Prior art date
Application number
HK98104232A
Other languages
English (en)
Inventor
Geoffrey Neil Woodruff
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27039510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1005166(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1005166A1 publication Critical patent/HK1005166A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98104232A 1990-01-02 1998-05-15 Gabapentin and its derivatives for treating neurodegenerative diseases HK1005166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45991290A 1990-01-02 1990-01-02
US07/615,151 US5084479A (en) 1990-01-02 1990-11-23 Novel methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
HK1005166A1 true HK1005166A1 (en) 1998-12-24

Family

ID=27039510

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104232A HK1005166A1 (en) 1990-01-02 1998-05-15 Gabapentin and its derivatives for treating neurodegenerative diseases

Country Status (7)

Country Link
US (1) US5084479A (xx)
EP (1) EP0446570B1 (xx)
JP (1) JP2903434B2 (xx)
AT (1) ATE125701T1 (xx)
DE (1) DE69111642T2 (xx)
DK (1) DK0446570T3 (xx)
HK (1) HK1005166A1 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
PT888286E (pt) * 1996-03-14 2002-04-29 Warner Lambert Co Novos amino acidos ciclicos substituidos como agentes farmaceuticos
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
CZ293248B6 (cs) * 1997-06-30 2004-03-17 Merz Pharma Gmbh & Co. Kgaa 1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
KR100589066B1 (ko) 1997-10-27 2006-06-13 워너-램버트 캄파니 엘엘씨 약제로서 유용한 시클릭 아미노산 및 그의 유도체
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
AU769038B2 (en) * 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
BR9910508B1 (pt) 1998-05-15 2012-01-24 preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
PT1289364E (pt) 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
KR100667721B1 (ko) * 2000-06-16 2007-01-15 테바 파마슈티컬 인더스트리즈 리미티드 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
US7141606B2 (en) * 2000-06-26 2006-11-28 Warner-Lambert Company Gabapentin analogues for sleep disorders
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
KR100958552B1 (ko) * 2001-06-11 2010-05-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
WO2002100344A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1485082A4 (en) * 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
US20040034248A1 (en) * 2002-04-16 2004-02-19 Taro Pharmaceutical Industries, Ltd. Process for preparing gabapentin
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
CN102429882B (zh) 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US20220296548A1 (en) * 2019-10-25 2022-09-22 Kyoto University Preventative or therapeutic agent for tauopathy
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
DE69111642T2 (de) 1996-01-25
JPH04210915A (ja) 1992-08-03
EP0446570A2 (en) 1991-09-18
EP0446570B1 (en) 1995-08-02
DK0446570T3 (da) 1995-11-27
EP0446570A3 (en) 1992-04-01
DE69111642D1 (de) 1995-09-07
ATE125701T1 (de) 1995-08-15
US5084479A (en) 1992-01-28
JP2903434B2 (ja) 1999-06-07

Similar Documents

Publication Publication Date Title
HK1005166A1 (en) Gabapentin and its derivatives for treating neurodegenerative diseases
SE8704204L (sv) Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma
MY115977A (en) Synthetic excitatory amino acids
FI101303B (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamin o-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino£2,1-a|£2|bentsatsep iini- ja -oksatsino- ja -tiatsino£3,4-a|£2|bentsatsepiini-4-karboksyyl ihappojohdannaisten valmistamiseksi
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
EP0552240A4 (en) New method of treating depression
NZ234672A (en) N-(1,2,3,4-tetrahydro-9-acridinyl)amide and carbamate derivatives and pharmaceutical compositions
HU9402933D0 (en) Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components
KR0148212B1 (en) Phenylalkan (en)oic acids
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
CA2188176A1 (fr) (oxo-1 alkyl) amino-2, deoxy-2 glucopyranoside de dihydroxy - 2,3 propyl, leur procede de preparation et leurs utilisations
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
PL310655A1 (en) Derivatives of hydroxymethylfurasane carboxylic acid and their application in treating cardiovascular diseases
AU1237592A (en) Iloprost effective against cerebral malaria
GR3015685T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders.
TW224488B (xx)
CZ281393B6 (cs) Způsob výroby 6-(substituovaných amino)-propionyl derivátů forskolinu
HUT56559A (en) Process for producing ascorbinic acid derivatives and pharma
EP0381114A3 (en) Exo-3',4'-0-benzylidene-3"-demethylchartreusin and its salts
DE69930880D1 (de) Bicyclische(3.1.0)hexane und verwandte Verbindungen
FR2708484B1 (fr) Procédé d'amélioration du broyage des minéraux.
ZA9010083B (en) New process for the preparation of mojirimycin and related compounds
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis
ATE105832T1 (de) Verfahren zur herstellung von staubfreiem silbernitrat.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090102